Older Adults With Depression Got More Relief When Their Antidepressant Came With a Daily Probiotic
A clinical trial published today in the Journal of the American Geriatrics Society has found that adults aged 60 and older with moderate depression experienced meaningfully greater reductions in both depressive and anxiety symptoms when a daily probiotic supplement was added to their standard antidepressant regimen — compared with a placebo group that continued the same medication alone. Biological data backed the finding: the probiotic group showed higher serum levels of brain-derived neurotrophic factor (BDNF), a protein that governs the survival and growth of neurons, and measurable shifts in gut bacteria composition consistent with enhanced gut-brain axis signaling.
The study, known as the PRODG trial, is the first randomized, double-blind, placebo-controlled trial specifically designed to test probiotic adjunct therapy in a geriatric depression population. For the tens of millions of older adults worldwide whose depressive symptoms are only partially controlled by medication — a group that is widely undertreated and largely absent from earlier microbiome-mental health research — today’s findings point to a low-cost, biologically grounded option worth pursuing in larger studies.
What the PRODG Trial Did
The trial enrolled 58 participants across multiple sites in India. All were at least 60 years old, had a diagnosis of moderate unipolar depression, and were already receiving standard antidepressant medication. Researchers randomly assigned half to receive a daily probiotic supplement alongside their existing treatment; the other half received an identical-looking placebo under the same conditions.
The intervention period ran for 12 weeks, followed by a further 12-week post-treatment follow-up — giving the research team a 24-week total window to track both immediate effects and whether any gains persisted after supplementation ended. The trial’s NCT-registered multi-center design and inclusion of biological markers alongside psychological scales gave it a level of rigor uncommon in earlier work.
First author Preeti Sinha and co-corresponding authors Dr. Saibal Das, of the Indian Council of Medical Research — National Institute for Research in Bacterial Infections in Kolkata, and Dr. Abhinaba Ghosh, a physician-neuroscientist at the Tata Medical Center, also in Kolkata, led the research.
What the Data Showed
Both groups improved substantially over the course of the study — an expected result, given that all participants continued antidepressant therapy. The probiotic group, however, pulled ahead on validated psychological rating scales measuring depression and anxiety severity, with gains that went beyond what the placebo group achieved.
The biological data told a parallel story. Participants in the probiotic arm showed greater increases in serum BDNF — a key marker for neuroplasticity and neuron survival that is reliably lower in people with depression and reliably higher in people who respond well to treatment. Their fecal microbiota profiles also showed meaningful compositional changes in gut bacteria, consistent with the kind of shifts researchers associate with enhanced communication along the gut-brain axis.
One important caveat: the probiotic group did not show clear additional gains in overall quality of life compared with the placebo group. The authors describe the study as a proof-of-concept pilot, not a definitive clinical recommendation, and they plan to conduct a larger follow-up trial based on these results.
How Probiotics Reach the Brain: The Gut-Brain Axis Mechanism
The gut-brain axis is the two-way biochemical signaling network that connects the gastrointestinal tract to the central nervous system through the enteric nervous system, the vagus nerve, the immune system, and endocrine pathways. Gut bacteria, which number in the trillions in a healthy adult, influence this network through several chemical channels — and this is where the PRODG trial’s BDNF finding becomes mechanistically significant.
When a probiotic shifts gut microbiome composition, the altered bacterial community produces short-chain fatty acids, particularly a molecule called butyrate. Butyrate can cross the blood-brain barrier and directly upregulate BDNF expression in the hippocampus — the brain region most consistently affected by depression and most dependent on BDNF for neuronal maintenance. Separately, gut bacteria influence the expression of tryptophan hydroxylase 1, the rate-limiting enzyme for serotonin synthesis in the gut’s enterochromaffin cells. That peripheral serotonin then activates vagal afferent fibers, which transmit signals to the brain stem and onward to mood-regulating circuits.
This matters for understanding the PRODG findings because conventional antidepressants — SSRIs in particular — raise BDNF by a different upstream route: they block serotonin reuptake at the synapse, which over weeks triggers downstream cascades that eventually increase hippocampal BDNF expression. Probiotic-mediated butyrate production activates a separate molecular pathway to the same endpoint. The two mechanisms are complementary rather than redundant, which is why a probiotic added on top of an antidepressant — rather than instead of one — may produce measurably greater benefit than either approach alone.
Probiotics also suppress pro-inflammatory cytokines, and chronic low-grade inflammation is independently known to suppress BDNF production. Reducing that inflammatory load gives BDNF production room to recover from another direction.
Why Older Adults Are a Distinct Research Gap
Depression in adults over 60 is among the most undertreated clinical conditions globally. The WHO estimates that depressive disorders affect between 10 and 20 percent of older adults across different regions; some meta-analyses of geriatric populations in lower-income countries place the figure far higher. Older adults are less likely to receive an accurate diagnosis — their symptoms are frequently attributed to physical illness or natural aging — and an 85 percent treatment gap has been documented in some settings.
Aging also alters the gut microbiome in ways that may compound depression risk. Microbial diversity decreases with age, communities shift toward more pro-inflammatory configurations, and the abundance of bacteria that produce beneficial short-chain fatty acids often declines. These changes parallel the neuroinflammatory and BDNF-suppressive processes observed in geriatric depression, suggesting the gut-brain axis may be a particularly important therapeutic target in this population — yet most earlier probiotic-mental health trials enrolled younger or mixed-age cohorts and rarely tested adjunct use alongside existing antidepressants.
The PRODG trial addressed both gaps directly. Its exclusive focus on adults 60 and older with active moderate depression receiving concurrent antidepressant treatment, combined with its multi-center design, biological outcome measures, and 24-week follow-up, represents the most rigorous test of this specific intervention in this specific population to date.
What the Evidence Does and Does Not Establish
As a pilot trial of 58 participants, the PRODG study was not statistically powered to produce definitive clinical guidance. The trial was conducted at sites in India, and questions remain about whether results generalize across populations with different dietary patterns, baseline microbiome compositions, and healthcare settings. The specific probiotic formulation, optimal dosing, and duration of effect all require further study. The lack of an observed quality-of-life benefit is also a meaningful absence.
The broader field of psychobiotics — probiotics investigated for their mental health effects — has generated consistent positive signals across multiple prior trials. A 2025 review of 19 depression RCTs found that while all 19 showed improvement with probiotic treatment, only 14 showed gains that clearly exceeded those in the placebo group. There is no consensus yet on which strains, doses, or durations work best for which patients.
Probiotics are generally considered safe for healthy adults, and no adverse interactions with standard antidepressants have been documented. However, clinicians advise that people with severely compromised immune systems should not use them without medical supervision, as live microorganisms can rarely become opportunistic in vulnerable patients.
Co-corresponding author Dr. Saibal Das said the team plans a larger-scale follow-up trial based on the PRODG results, with the goal of developing affordable treatment solutions with meaningful public health reach.
Frequently Asked Questions
Can a daily probiotic actually help with depression in older adults?
A clinical trial published today in the Journal of the American Geriatrics Society found that adults 60 and older with moderate depression showed greater improvements in depressive and anxiety symptoms when a daily probiotic was added to their standard antidepressant, compared with a placebo group. The probiotic group also showed higher BDNF levels, a biological marker linked to better depression outcomes. The trial enrolled only 58 participants and did not find improvement in overall quality of life, so the finding is considered promising but preliminary pending larger studies.
How do gut bacteria affect mood and brain chemistry?
The gut-brain axis is a two-way signaling network connecting the gastrointestinal tract and the brain through the vagus nerve, the enteric nervous system, immune signaling, and endocrine pathways. Probiotic bacteria produce short-chain fatty acids, especially butyrate, which can cross the blood-brain barrier and stimulate BDNF production in the hippocampus. They also influence serotonin synthesis in the gut, reduce pro-inflammatory cytokines, and modulate the stress hormone cortisol through the hypothalamic-pituitary-adrenal axis — multiple complementary pathways that may together improve mood and neurological resilience.
If antidepressants already raise BDNF, why would a probiotic add anything?
Antidepressants such as SSRIs raise BDNF by blocking serotonin reuptake at the synapse, triggering downstream signaling cascades that eventually increase BDNF expression. Probiotics raise BDNF via a mechanistically distinct upstream pathway: gut bacteria produce butyrate, which crosses the blood-brain barrier and directly upregulates BDNF gene expression in the hippocampus. Because the two pathways are separate, they can operate simultaneously and additively — which is the biological rationale for why combining a probiotic with an antidepressant may produce measurably greater benefit than either approach alone.
Is it safe to take a probiotic alongside antidepressants?
Current evidence suggests that probiotics are generally safe for healthy older adults and that no adverse interactions with antidepressants have been documented. The PRODG trial reported no safety concerns among its 58 participants. However, people with compromised immune systems should consult a physician before starting probiotics, as live microorganisms can rarely cause opportunistic infections in vulnerable patients. Anyone considering adding a probiotic to an existing antidepressant regimen should discuss it with their prescribing clinician rather than adjusting treatment independently.
Enjoyed this article? Sign up for our newsletter to receive regular insights and stay connected.